• Possible therapeutic targets identified for ALS and frontotemporal dementia

    Wednesday September 14th 2022

  • ImmuneWatch secures a VLAIO grant to tailor their technology to vaccine developers

    Monday September 12th 2022

  • Precirix enters into collaboration with Eckert & Ziegler for the development of its 68Ga-based compounds

    Monday September 12th 2022

  • Carroucell raises €1.5 million to introduce breakthrough microcarriers and customizable processes to cell and gene therapy market

    Thursday September 8th 2022

  • New three-year BIMZELX®▼ (bimekizumab) data reinforce long-term maintenance of complete skin clearance in moderate to severe plaque psoriasis

    Wednesday September 7th 2022

  • BioLizard is now an Official Illumina Connected Analytics Implementation Partner

    Monday September 5th 2022

  • Nieuwe investering voor HERAN Partners: Aspect Analytics

    Monday September 5th 2022

  • Pathomation announces new release of the “My Pathomation” cloud platform for digital pathology

    Friday September 2nd 2022

  • Your news here?

  • Biocartis initiates commercialization in Europe of SkylineDx’s innovative Merlin™ Assay (CE-IVD) for melanoma patients

    Thursday September 1st 2022

  • reMYND identifies novel target and small molecules with potential to halt and reverse disease progression in Huntington’s disease through oral administration

    Wednesday August 31st 2022

  • Autoimmune disorders increase risk of cardiovascular disease

    Saturday August 27th 2022


Strategic Partners